Link Between Liver Fibrosis in MASLD and Heart Disease Varies by Blood Sugar Control

A new study published in Hepatology Communications reveals that the relationship between liver fibrosis and atherosclerotic cardiovascular disease (ASCVD) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) depends significantly on their glycemic status. The findings suggest that blood sugar control plays a critical role in determining how liver fibrosis affects heart disease risk. This discovery is important for patients with MASLD, as it highlights the interconnection between metabolic disorders and cardiovascular health. Healthcare providers may need to tailor treatment strategies based on individual glycemic control to better manage both liver and heart disease risk.